Sorry as background to my previous, boxing IP into discrete segments is probably the way to go.
Quarantining IP in a box that can be transferred out of the company is worth a lot more to a global pharma/biotech buyer, than the average punter on the ASX.
in the above example of Roche license deal for say EU region is amplified by factoring in the 17x add on to the market cap:
US$100m per annum profit x 17PE = US$1.7B added to the Roche’s current ~US$250B market cap; 0.0068 is not much add on but still something!
Sorry as background to my previous, boxing IP into discrete...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.020(1.74%) |
Mkt cap ! $659.0M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.19 | $1.13 | $187.3K | 162.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5698 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 938 | 1 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |